Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Evaluation of the prognostic potential of EGFL7 in pilocytic astrocytomas

Full text
Author(s):
Brunhara, Bruno B. [1, 2] ; Becker, Aline P. [3] ; Neder, Luciano [1] ; Goncalves, Paola G. [4, 1] ; de Oliveira, Cristiane [4, 1] ; Clara, Carlos A. [5] ; Reis, Rui M. [1, 6, 7] ; Bidinotto, Lucas T. [4, 1, 2]
Total Authors: 8
Affiliation:
[1] Barretos Canc Hosp, Mol Oncol Res Ctr, Rua Antenor Duarte Villela 1331, BR-14784400 Barretos, SP - Brazil
[2] Dr Paulo Prata FACISB, Barretos Sch Hlth Sci, Barretos - Brazil
[3] Ohio State Univ, Dept Radiat Oncol, Columbus, OH 43210 - USA
[4] Sao Paulo State Univ UNESP, Botucatu Med Sch, Dept Pathol, Botucatu, SP - Brazil
[5] Barretos Canc Hosp, Dept Neurosurg, Barretos - Brazil
[6] Univ Minho, Life & Hlth Sci Res Inst ICVS, Sch Med, Braga - Portugal
[7] ICVS PT Govt Associate Lab 3Bs, Braga - Portugal
Total Affiliations: 7
Document type: Journal article
Source: NEUROPATHOLOGY; NOV 2020.
Web of Science Citations: 0
Abstract

Pilocytic astrocytoma (PA) is the most frequent solid neoplasm in childhood. It has a good 5-year overall survival (90% in childhood and 52% in adults). However, up to 20% of patients experience residual tumor growth, recurrence, and death. Although the main genetic alteration of PAs, including KIAA1549:BRAF fusion, involves chromosome 7q34, we previously found frequent loss in chr9q34.3 locus in a small subset of these tumors. Among the genes present in this locus, EGFL7 is related to poor prognosis in several tumor types. In this study, we aimed to assess EGFL7 expression through immunohistochemistry, and to evaluate its prognostic value in a series of 64 clinically and molecularly well-characterized pilocytic astrocytomas. We found high expression of EGFL7 in 71.9% of patients. Low EGFL7 expression was associated with older patients, the mean age mainly older than 11 years (P = 0.027). EGFL7 expression was not associated with presence of KIAA1549:BRAF fusion, BRAF mutation, FGFR1 mutation, nor FGFR1 duplication. Moreover, high EGFL7 expression was associated with high FGFR1 (P = 0.037) and 5 `-deoxy-5 `-methyltioadenosine phosphorylase (MTAP) (P = 0.005) expression, and with unfavorable outcome of patients (P = 0.047). Multivariate analysis revealed low EGFL7 expression related to older patients and high EGFL7 expression related to retained expression of MTAP. In addition, we found a borderline significance of unfavorable outcome and high EGFL7 expression. Finally, EGFL7 expression was not associated with overall or event-free survival of PA patients. Our findings point to EGFL7 expression as a novel candidate prognostic marker in PA, which should be further investigated. (AU)

FAPESP's process: 16/23919-8 - Evaluation of the prognostic potential of the genes present in 9q34.3 in pilocytic astrocytomas
Grantee:Bruno Bertozi Brunhara
Support type: Scholarships in Brazil - Scientific Initiation
FAPESP's process: 12/19590-0 - Mutational profile of glioblastoma primary cultures
Grantee:Rui Manuel Vieira Reis
Support type: Regular Research Grants
FAPESP's process: 17/09749-5 - Evaluation of the expression and potential prognosis of the genes present in the chr9p22.1-p21.3 locus in gliomas
Grantee:Paola Gyuliane Gonçalves
Support type: Scholarships in Brazil - Master
FAPESP's process: 16/21727-4 - Analysis of the prognostic potential of the genes present in the locus 9p22.1-p21.3 in gliomas
Grantee:Lucas Tadeu Bidinotto
Support type: Regular Research Grants